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Abstract: We have screened small molecule libraries spe-
cifically for inhibitors that target WWP2, an E3 ubiquitin
ligase associated with tumour outgrowth and spread. Se-
lected hits demonstrated dose-dependent WWP2 inhibi-
tion, low micromolar IC50 values, and inhibition of PTEN
substrate-specific ubiquitination. Binding to WWP2 was
confirmed by ligand-based NMR spectroscopy. Further-
more, we used a combination of STD NMR, the recently
developed DEEP-STD NMR approach, and docking calcula-
tions, to propose for the first time an NMR-validated 3D
molecular model of a WWP2-inhibitor complex. These first
generation WWP2 inhibitors provide a molecular frame-
work for informing organic synthetic approaches to im-
prove activity and selectivity.
There are approximately 600 E3 ligases in the human genome,
and they can be sub-divided into RING type and HECT domain
ligases.[1] Within the HECT E3s is a small group (9 in total) re-
ferred to as the Nedd4 superfamily, which includes the WWP1,
WWP2, Nedd4, ITCH and Smurf2 Ub ligases.[2] The 3D crystal
structures have been resolved for the HECT domains within
Nedd4,[3] WWP1,[4] and WWP2.[5, 6] Accumulating evidence sug-
gests that the Nedd4 ligases, and notably WWP1 and WWP2,
are frequently mis-expressed in cancer.[7–9] Their overexpression
in animal models causes increased tumour outgrowth,[10] and
they also selectively control key oncogenic signaling events
linked to both cancer initiation and spread.[11]
There have been a number of recent attempts to develop
HECT ligase inhibitors, and more specifically targeting the
Nedd4 sub-family. Heclin was identified from a bicyclic peptide
library screen and can selectively inhibit Smurf2, Nedd4 and
WWP1 by inducing a conformational change that causes oxida-
tion of the active site cysteine.[12] Chlomipramine emerged as a
candidate ITCH ligase inhibitor based on an enzymatic assay-
based high throughput screen and was shown to block both
ITCH auto-ubiquitination and substrate-specific p73 ubiquitina-
tion, although IC50 values are in the low millimolar range.[13]
Using a covalent tethering method, a new class of Nedd4
ligase inhibitors were identified and shown to react with a
non-catalytic cysteine to hinder ubiquitin binding to this exo-
site and subsequent enzymatic processivity.[14] Additional at-
tempts to discover Nedd4 inhibitors have utilised in silico
modelling approaches supported by thermal shift binding ex-
periments and revealed that derivatives of indole-3-carbinol
may also bind to the processivity exosite in the Nedd4 catalytic
HECT domain and inhibit substrate-specific ubiquitination
linked to oncogenic signalling events.[15,16]
Here, we focused our efforts on developing small molecule
inhibitors of the WWP2 ubiquitin ligase, an enzyme that can
cause ubiquitin-dependent degradation of specific tumour
suppressor proteins that are commonly lost in many types of
cancer, namely Smad transcription factors, PTEN, and Oct4. To
that aim, we have used high-throughput screening to identify
hits from the NCI Diversity Set V and NCI Approved Oncology Set
V small molecule libraries, we have confirmed binding to
WWP2 by NMR spectroscopy, and used a combination of STD
NMR, DiffErential EPitope mapping (DEEP)-STD NMR and dock-
ing calculations to generate for the first time an NMR-validated
3D molecular model of a WWP2-inhibitor complex. To discover
first generation WWP2 ubiquitin ligase inhibitors we used a 96-
well plate format high-throughput screen (HTS) using recombi-
nant proteins and auto-ubiquitination as a readout for WWP2
activity (Figure 1a).
Initially, to develop and optimise the HTS assay full-length
WWP2 (WWP2-FL) expressed as a GST fusion protein in bacte-
ria was attached onto glutathione-coated plates and then incu-
bated with recombinant E1, E2 enzymes and Flag-tagged ubiq-
uitin (Supporting Information Figure S1a). The specificity for
WWP2 auto-ubiquitination was confirmed by detection of Ub-
Flag conjugated WWP2 in the presence of all assay compo-
nents and confirmed using a catalytically inactive WWP2-FLC838A
mutant (Supporting Information Figure S1b). Next, we used
this assay to screen the NCI Diversity Set V and NCI Approved
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Oncology Set V small molecule libraries consisting of 1,593 and
450 compounds, respectively. The initial screens were run as
single shot assays at a concentration of 10 mm and 0.1%
DMSO, with Z’ values over 0.5 suggesting that these plate
assays were robust. The controls for each library screen
showed no significant difference between the buffer and E3
only controls and no significant effect was observed in the
presence of DMSO (Supporting Information Figure S1c). Results
were normalised using the high and low controls to calculate
the percentage residual activity compared to the DMSO con-
trol. A threshold of 70% (>2 SD from the DMSO control mean)
was used to determine which compounds would be selected
for further testing. We identified 24 initial hits from the NCI Di-
versity Set V screen, but no hits emerged from the NCI Oncolo-
gy set (Figure 1a and Supporting Information Figure S1d). Po-
tential hits emerging from the single shot assays were then
tested in triplicate under the same assay conditions and at
10 mm compound concentration, and 17 of the initial 24 hits
demonstrated significant decrease in WWP2 activity (Fig-
ure 1b). These were then further ranked more stringently
based on <20% residual activity thresholds, and further de-se-
lected based on dose-dependent WWP2 inhibition (Supporting
Information Figure S2). In total, 10 potential hit inhibitors with
varied structural compositions were identified and the majority
of these gave IC50 values in the low micromolar range (Sup-
porting Information Table S1), and five of these inhibitors had
IC50 values below 3 mm (Table 1).
We next further analysed all 10 selected hit compounds
based on counter assays against E1, E2, Nedd4 and WWP1
ubiquitin ligases. Since the WWP2 auto-ubiquitination is de-
pendent on prior sequential activation of ubiquitin by E1 and
E2 ubiquitin ligases, we addressed whether any of the lead in-
hibitors were affecting this ubiquitin priming step earlier
within in the auto-ubiquitination cascade. We therefore devel-
oped and optimised ubiquitination assays to measure UbcH7
(E2) and Uba1 (E1) activities. For UbcH7, we used a similar
plate assay approach as used to measure E3 activity but used
bacterially His-tagged UbcH7 and bound this protein onto
nickel-coated 96-well plates. Once the assay was optimised to
obtain significant 100% and 0% activity controls, compounds
were tested at the same initial concentrations as used in the
GST-WWP2-FL screening, and no significant decrease in activity
was observed for all compounds in the His-E2 ubiquitination
assay (Supporting Information Figure S3a). To assess com-
pound effects on E1 activity, we used a different gel-based ap-
proach due to difficulties in developing robust and reproduci-
ble plate assays. Recombinant His-Uba1 and ubiquitin undergo
E1-mediated transthiolation when incubated together and the
formation of higher molecular weight mono-Ub-E1 conjugates
was clearly apparent when separated by SDS-PAGE and stained
with Coomassie Blue. In the presence of the WWP2 lead inhibi-
tory compounds we found no discernible impact on E1 ubiqui-
tin conjugation (Supporting Information Figure S3b). Hit com-
pounds were next tested against Nedd4 and WWP1 to find out
whether they were capable of inhibiting other HECT E3 ligases
in the same family as WWP2. GST-tagged Nedd4 and His-
tagged WWP1 were immobilised onto glutathione coated and
nickel coated plates, respectively. Auto-ubiquitination levels
were determined using HRP-conjugated anti-Flag antibody and
TMB substrate. Both Nedd4 and WWP1 produced a significant
increase in OD when in the presence of E1, E2, and ubiquitin,
unlike all other reactions (Supporting Information Figure S3c).
There was no significant difference between reactions which
lacked one or more components, showing that Nedd4 and
WWP1 are capable of auto-ubiquitination under these assay
conditions. All inhibitors tested demonstrated some degree of
Figure 1. High throughput screen for WWP2 inhibitors. (a) HTS assays for
NCI Diversity Set V were carried out using 10 mm compound at 0.1% DMSO
in single shot with internal controls for 100% activity (DMSO) and 0% activi-
ty (E3 only) on each individual plate. All assays were normalised using 100%
and 0% controls and had a threshold of 70% as indicated by the yellow
line. 0.5<Z’<0.9 for all single shot assays. (b) Auto-ubiquitination assay on
24 Diversity set V hits at 10 mm and 0.1% DMSO with a threshold set at 20%
as indicated by the yellow line.
Table 1. Summary of selected hits from WWP2 inhibitor screen and IC50
values. Data for STD-NMR and CPMG are included, and (?) indicates in-
conclusive data due to poor solubility and/or low signal/noise ratios.
Cpd./NSC Structure IC50 (mm) STD-NMR CPMG
1/2805 0.38 3 3
7/228155 0.84 V V
12/44750 0.85 ? ?
19/228150 1.29 ? ?
20/288387 2.30 3 3
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inhibition against all three E3 ubiquitin ligases, although sever-
al of the inhibitors tested were more potent against WWP2.
Compounds 1, 2 and 12 showed no significant difference be-
tween the HECT E3 ligases, implying that these compounds
are not selective towards one of the ligases (Supporting Infor-
mation Figure S3d). Nevertheless, these three compounds do
show a significant reduction in activity for all three proteins.
Compounds 7 and 19 showed a significant difference between
WWP2 and WWP1, and WWP1 and Nedd4 but 7 and 19 pre-
sented no difference between WWP2 and Nedd4. Interestingly,
compounds 16, 17, 18, 20 and 21 showed increased inhibition
towards WWP2 over WWP1 and Nedd4 (Supporting Informa-
tion Figure S3d). We next tested for substrate-specific effects,
and determined whether these inhibitors could affect WWP2-
dependent PTEN ubiquitination. Reactions contained E1, E2,
WWP2, PTEN, ubiquitin and ATP and were analysed by western
blotting. In the presence of selected hit compounds represent-
ing a broad range of IC50 values based on the HTS assay, it is
clear that each can robustly inhibit WWP2-dependent PTEN
ubiquitination (Figure 2).
Ligand-based NMR was then used to confirm binding of hit
compounds to the WWP2 HECT catalytic domain. We used i),
Saturation Transfer Difference (STD) NMR and ii), Carr–Purcell–
Meiboom–Gill (CPMG) NMR experiments, two widely used
techniques for lead screening in drug discovery.[17] STD NMR
spectroscopy relies on protein-selective saturation being trans-
ferred only to the bound ligands in fast exchange with the re-
ceptor.[18,19] Hence, the presence of signals in the STD differ-
ence spectra of a sample containing one ligand (or more) in
the presence of a receptor indicates binding. CPMG NMR ex-
periments, also called T2-filter experiments, rely on a filter (re-
peating spin-echo building blocks in the pulse sequence)
whose aim is to eliminate the signals coming from large mole-
cules (usually having a short transverse relaxation time, T2).
[20]
Bound ligands transiently acquire a T2 similar to that of the re-
ceptor, and so their signal will be filtered out as well. In the
CPMG spectrum, the absence (or strong reduction) of ligand
signals in the presence of a receptor indicates binding.
The NMR screening provided clear-cut results for six of the
hit compounds, as shown by positive binding results in both
the STD and CPMG NMR experiments (1, 2, 16, 17, 18 and 20,
see Table 1, Supporting Information Table S1 and Figure S4).
Compounds 12, 19 and 21 were excluded as they showed
very weak signals both in the binding experiments and in the
control spectra, probably ascribable to solubility issues; while
compound 7 showed no STD signals. It is important to high-
light that fast exchange between the free and the bound state
is an essential condition for STD NMR.[21] The STD signal is de-
tected in the ligand free state; if the ligand resides within the
binding pocket for a long period of time, the saturation is not
sufficiently accumulated during the saturation time. The low
IC50 value determined for compound 7 (0.84 mm) and the ab-
sence of STD signals for this hit could indicate too strong an
affinity of binding. This would make compound 7 unsuitable
for ligand-based NMR observation, but the results do not nec-
essarily exclude it as a binder.
STD NMR has also great potential in structurally elucidating
the binding mode of a ligand in complex with the protein at
atomic detail, providing the binding epitope mapping of the
ligand.[21] Among the six identified binders based on STD-NMR
data, we selected NSC288387 (compound 20) since it showed
the clearest STD signals (probably as a consequence of its mid-
range IC50, of 2.30 mm) to deepen the structural analysis by
performing STD binding epitope mapping. The STD binding
epitope mapping (Figure 3a) suggests that the main recogni-
tion element in the complex between WWP2 HECT and com-
pound 20 is the unsubstituted N-phenyl ring (labelled B in
Figure 3); ring A and the aliphatic ether adjacent to it show
weaker interactions, suggesting that this part of the molecule
would be the most solvent exposed.
We then used computational techniques to identify the
binding site on the WWP2 HECT domain (based on the PDB
ID: 4Y075) and to then dock compound 20 into the putative
binding pocket (see Supporting Information Table S2 and Fig-
ure 3b). The lowest energy docking solution, shown in Fig-
ure 3b (see also Supporting Information Table S2), was in very
good agreement with the binding epitope experimentally de-
termined by STD NMR. Furthermore, as a step further for the
Figure 2. Effects of WWP2 inhibitors on substrate-specific PTEN ubiquitina-
tion. In vitro GST-PTEN ubiquitination reactions in the absence and presence
of compounds, analysed using western blotting with anti-GST and anti-His
antibodies.
Figure 3. Differential epitope mapping of compound 20 (NSC288387) in
complex with WWP2-HECT domain. a) STD Binding epitope mapping,
b) lowest energy docking solution of NSC288387 onto WWP2 HECT domain,
c) DEEP-STD factors (1.5 ppm/0.5 ppm) and d) details of the binding pocket
for NSC288387. In d), residues within 5 a from the ligand are shown, protein
protons resonating at 0.5 ppm and 1.5 ppm are enclosed in a green and
orange surface, respectively (see also Supporting Information Table S5).
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validation of the 3D model of the complex, we employed the
newly developed DEEP-STD NMR approach (relying on protein
irradiation at differential frequencies) which allows the identifi-
cation of the types of amino-acids lining the binding pocket
that make inter-molecular contacts with specific single protons
of the ligand.[22] The DEEP-STD NMR data obtained by differen-
tial irradiation of the protein at 0.50 and 1.50 ppm (Figure 3c)
provided additional experimental support for the 3D molecular
model of the complex generated by the docking approach.
Frequencies 0.50 and 1.50 ppm correspond to methyl groups
of valine and isoleucine, and the arginine b/g protons, respec-
tively (see Supporting Information Table S3 and S4). Closer in-
spection of the docking solution in the putative binding
pocket reveals the presence of Val806 and Arg803 at close dis-
tances from ring A of the ligand (Figure 3d and Supporting In-
formation Table S5).
Remarkably, the docking solution structure shows ligand
protons c, d and e pointing towards the methyl group of
Val806, and protons f and g, pointing towards the Arg803, on
the opposite side of the binding pocket. This is in perfect
agreement with the DEEP-STD factors (1.5/0.5 ppm) observed
for these protons (Figure 3c): protons c, d and e show negative
DEEP-STD factors, and protons f and g show positive DEEP-STD
factors (suggesting vicinity with protein residues resonating at
0.5 and 1.5 ppm, respectively). The excellent match between
the docking solution of compound 20 in the putative binding
pocket and the pharmacophore of both the ligand and the
binding site (obtained by STD NMR and DEEP-STD NMR, re-
spectively) give us solid ground to propose the model as the
first 3D structure of a WWP2 inhibitor bound to its target
(Figure 3 and Supporting Information Figure S5). Furthermore,
this NMR-validated model is supported by molecular dynamics
simulation studies demonstrating stability of the complex
(Supporting Information Figures S6–S8).
In summary, the compounds discovered in this study repre-
sent the first generation of WWP2 ubiquitin ligase inhibitors.
Additionally, through a combination of HTS, ligand-based NMR,
DEEP-STD NMR and docking calculations we have been able to
propose for the first time a 3D molecular model of a WWP2-in-
hibitor complex. Collectively, these data provide a framework
for developing new classes of ubiquitin ligase inhibitors that
can progress through further organic synthesis to improve
compound activity and specificity and have potential to gener-
ate lead therapeutic compounds. We are currently working to-
wards unravelling the mechanism of inhibition by these novel
ligands and further probing the ligand binding sites using
combined DEEP-STD NMR and crystallography approaches. We
anticipate that, building up from this work, subsequent lead
optimization will provide novel analogues that can progress
through to potential therapeutic compounds.
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